Structural basis of ligand selectivity and disease mutations in cysteinyl leukotriene receptors

Anastasiia Gusach, Aleksandra Luginina, Egor Marin, Rebecca L. Brouillette, Élie Besserer-Offroy, Jean Michel Longpré, Andrii Ishchenko, Petr Popov, Nilkanth Patel, Taku Fujimoto, Toru Maruyama, Benjamin Stauch, Margarita Ergasheva, Daria Romanovskaia, Anastasiia Stepko, Kirill Kovalev, Mikhail Shevtsov, Valentin Gordeliy, Gye Won Han, Vsevolod KatritchValentin Borshchevskiy, Philippe Sarret, Alexey Mishin, Vadim Cherezov

    Research output: Contribution to journalArticlepeer-review

    31 Citations (Scopus)


    Cysteinyl leukotriene G protein-coupled receptors CysLT1 and CysLT2 regulate pro-inflammatory responses associated with allergic disorders. While selective inhibition of CysLT1R has been used for treating asthma and associated diseases for over two decades, CysLT2R has recently started to emerge as a potential drug target against atopic asthma, brain injury and central nervous system disorders, as well as several types of cancer. Here, we describe four crystal structures of CysLT2R in complex with three dual CysLT1R/CysLT2R antagonists. The reported structures together with the results of comprehensive mutagenesis and computer modeling studies shed light on molecular determinants of CysLTR ligand selectivity and specific effects of disease-related single nucleotide variants.

    Original languageEnglish
    Article number5573
    JournalNature Communications
    Issue number1
    Publication statusPublished - 1 Dec 2019


    Dive into the research topics of 'Structural basis of ligand selectivity and disease mutations in cysteinyl leukotriene receptors'. Together they form a unique fingerprint.

    Cite this